Molecular parameters of genome instability: Roles of fragile genes at common fragile sites

Journal of Cellular Biochemistry

Volumn 104, Issue 5, 2008, Pages 1525-1533

  Pichiorri, Flavia ^a   Ishii, Hideshi ^b,c   Okumura, Hiroshi ^a   Trapasso, Francesco ^d   Wang, Ya ^e   Huebner, Kay ^a,f  

^a OHIO STATE UNIVERSITY   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Common fragile sites; DNA damage checkpoint; DNA repair; FHIT

Indexed keywords

FERREDOXIN; FRAGILE HISTIDINE TRIAD PROTEIN; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

APOPTOSIS; ATR PROTEIN GENE; CANCER CELL; CELL CYCLE PROGRESSION; CELL DIVISION; CELL PROTECTION; CELL STRESS; CHECKPOINT KINASE 1 GENE; CHROMOSOMAL INSTABILITY; CHROMOSOME G BAND; CHROMOSOME R BAND; CHROMOSOME STRUCTURE; COMMON FRAGILE SITE; DNA DAMAGE; DNA REPAIR; DNA STRAND; FRA3B GENE; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENE MAPPING; GENE REPLICATION; GENE SEQUENCE; GENE TARGETING; GENOME; HUMAN; HUS1 GENE; LIFESPAN; MAMMAL; MITOSIS; MUTATION; NONHUMAN; PHYSICAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PUBERTY; REPRODUCTION; REVIEW; SOMATIC CELL; YEAST;

ACID ANHYDRIDE HYDROLASES; CHROMOSOME FRAGILE SITES; DNA DAMAGE; GENOMIC INSTABILITY; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OXIDOREDUCTASES; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 50249162487     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21560     Document Type: Review

References (42)

1. Aqeilan RI, Croce CM. 2007. WWOX in biological control and tumorigenesis. J Cell Physiol 212:307-310.
2. Arlt MF, Durkin SG, Ragland RL, Glover TW. 2006. Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 5:1126-1133.
3. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.
4. Barzilai A, Yamamoto K-I. 2004. DNA damage responses to oxidative stress. DNA Repair (Amst) 3:1109-1115.
5. Bester AC, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Ben-Porat N, Von Kalle C, Fischer A, Kerem B. 2006. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther 13:1057-1059.
6. Chang NS. 2002. A potential role of p53 and WOX1 in mitochondrial apoptosis. Int J Mol Med 9:19-24.
7. Debatisse M, El Achkar E, Dutrillaux B. 2006. Common fragile sites mested at the interfaces of early and late-replicating chromosome bands. Cell Cycle 5:578-581.
8. Dhillon VS, Husain SA, Ray GN. 2003. Expresssion of aphidicolin-induced fragile sites and their relationship between genetic susceptibility in breast cancer, ovarian cancer, and non-small-cell lung cancer patients. Teratog Carcinog Mutagen Suppl 1:35-45.
9. El Achkar E, Gerbeau-Seureau M, Muleris M, Dutrillaux B, Debatisse M. 2005. Premature condenstion induces breaks at the interface of early and late replicating chromosome bands bearing common fragile sites. Proc Natl Acad Sci (USA) 102:18069-18074.
10. Freudenreich CH. 2007. Chromosome fragility: Molecular mechanisms and cellular consequences. Frontiers Biosci 12:4911-4924.
11. Glover TW, Berger C, Coyle J, Echo B. 1984. DNA polymerase a inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67:136-142.
12. Grgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-913.
13. Guler G, Uner A, Guler N, Engin H, Han SY, Hauck WW, Iliopoulos D, McCue P, Huebner K. 2004. The fragile genes, FHIT and WWOX, are coordinately inactivated in invasive breast cancer: Correlations with clinical features. Cancer 100:1605-1614.
14. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, Huebner K. 2005. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 55:471-478.
15. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. 2007. Wwox and Ap2γ expression levels predict tamoxifen response. Clin Can Res 13:6115-6121.
16. Hanukoglu I, Rapoport R, Weiner L, Sklan D. 1993. Electron leakage from the mitochondrial NADPH-adre-nodoxin reductase-adrenodoxin-P450scc (cholesterol side chain cleavage) system. Arch Biochem Biophys 305:489-498.
17. Heimreich A, Stout-Weider K, Hermann K, Schrock E, Heiden T. 2006. Common fragile sites are conserved features of human and mouse chromosomes and relate to large active genes. Genome Res 16:1222-1230.
18. Hu B, Han S, Wang X, Ottey M, Dicker A, Huebner K, Wang Y. 2005a. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 202:518-523.
19. Hu B, Wang H, Wang X, Lu HR, Huang C, Powell SN, Huebner K, Wang Y. 2005b. Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res 65:8613-8616.
20. Huebner K, Croce CM. 2003. Cancer and the FRA3B/FHIT fragile locus: It's a hit. Brit J Cancer 88:1501-1506.
21. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, McCorkell KA, Huebner K. 2006. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 232:27-36.
22. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kallio-niemi O-P, Barkardottir RB, Kovatich A, Schwarting R, Hauck WW, Huebner K, McCue PA. 1999. Reduced Fhit expression in familial and sporadic breast carcinomas. Cancer Res 59:2682-2689.
23. Ishii H, Mimori K, Inoue H, Inageta T, Ishikawa K, Semba S, Druck T, Trapasso F, Tani K, Vecchione A, Croce CM, Mori M, Huebner K. 2006. Fhit modulates the DNA damage checkpoint response. Cancer Res 66:11287-11292.
24. Ishii H, Wang Y, Huebner K. 2007. A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle 6:1044-1048.
25. 2 checkpoint. Oncogene 25:6037-6047.
26. Matsuyama A, Shiraishi T, Trapasso F, Alder H, Kuroki T, Mori M, Huebner K, Croce CM. 2003. Genome stability and fragility: Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2 are evolutionarily conserved but mitotically unstable. Proc Natl Acad Sci (USA) 100:4988-4993.
27. Ottey M, Han SY, Druck T, Barnoski B, McCorkell KA, Croce CM, Suarez CR, Fairchild C, Wang Y, Huebner K. 2004. Fhit deficient normal and cancer cells are mitomycin C and UVC resistant. Brit J Cancer 91:1669-1677.
28. Paulsen RD, Cimprich KA. 2007. The ATR pathway: Fine-tuning the fork. DNA Repair (Amst) 6:953-966.
29. Richardson C, Stark JM, Ommundsen M, Jasin M. 2004. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 23:546-553.
30. Ruiz-Herrera A, Castresana J, Robinson TJ. 2006. Is mammalian chromosomal evolution driven by regions of genome fragility? Genome Biol 7:R115 (doi:10.1186/gb-2006-7-12-r115).
31. Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, le Sage C, Chen BP, Chen DJ, Agami R, Kerem B. 2005. Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes Dev 19:2715-2726.
32. Schwartz M, Zlotorynski E, Kerem B. 2006. The molecular basis of common and rare fragile sites. Cancer Lett 232: 13-26.
33. Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison PN, Barnes LD, Croce CM, Huebner K. 2006. Fhit modulation of the Akt-Survivin pathway in lung cancer cells: Fhit tyrosine 114 is essential. Oncogene 25:2860-2872.
34. Shackelford RE, Kaufmann WK, Paules RS. 2000. Oxidative stress and cell cycle checkpoint function. Free Rad Bio Med 28:1387-1404.
35. Smith DI, Zhu Y, McAvoy S, Kuhn R. 2006. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 232:48-57.
36. Sonoda E, Hochegger H, Saberi A, Taniguchi Y, Takeda S. 2006. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair (Amst) 5:1021-1029.
37. Trapasso F, Krakowiak A, Cesari R, Arkles J, Yendamuri S, Ishii H, Vecchione A, Kuroki T, Bieganowski P, Pace HC., et al. 2003. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci USA 100:1592-1597.
38. Trapasso F, Pichiorri F, Gasparo M, Palumbo T, Raso C, Aqeilan RI, Gaudio E, Iuliano R, Okumura H, Di Leva G, Fabbri M, Birk DE, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM. 2007. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis. J Biol Chem DOI: 10.1074/jbc.M709062200
39. Tunca B, Ceccner G, Gebitikin C, Egeli U, Ediz B, Ercan I. 2002. Investigation of genetic susceptibility to non-small cell lung cancer by fragile site expression. Teratog Carcinog Mutagen 22:205-215.
40. Turner B, Ottey M, Potoczek M, Hauck WW, Pequignot E, Keck-Waggoner C, Zimonjic DB, Sevignani C, Aldaz M, McCue P, Palazzo J, Huebner K, Popescu NC. 2002. The FHIT/FRA3B locus and repair deficient cancers. Cancer Res 62:4054-4060.
41. Zhu M, Weiss RS. 2007. Increased common fragile site expression, cell proliferation defects, and apoptosis following conditional inactivation of mouse Hus1 in primary cultured cells. Mol Biol Cell 18:1044-1055.
42. Zlotorynski E, Rahat A, Skaug J, Ben-Porat N, Ozeri E, Hershberg R, Levi A, Scherer SW, Margalit H, Kerem B. 2003. Molecular basis for expression of common and rare fragile sites. Mol Cell Biol 23:7143-7151.